Loomis, Sayles & Company’s Ascendis Pharma ASND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $25.6M | Sell |
148,497
-26,416
| -15% | -$4.56M | 0.03% | 197 |
|
|
2025
Q1 | $27.3M | Sell |
174,913
-3,986
| -2% | -$621K | 0.04% | 193 |
|
|
2024
Q4 | $24.6M | Sell |
178,899
-5,724
| -3% | -$788K | 0.03% | 222 |
|
|
2024
Q3 | $27.6M | Buy |
184,623
+63,029
| +52% | +$9.41M | 0.04% | 213 |
|
|
2024
Q2 | $16.6M | Buy |
+121,594
| New | +$16.6M | 0.02% | 280 |
|
|
2021
Q3 | – | Sell |
-179,446
| Closed | -$23.6M | – | 887 |
|
|
2021
Q2 | $23.6M | Buy |
179,446
+6,862
| +4% | +$903K | 0.03% | 284 |
|
|
2021
Q1 | $22.2M | Buy |
172,584
+14,948
| +9% | +$1.93M | 0.03% | 273 |
|
|
2020
Q4 | $26.3M | Buy |
157,636
+32,626
| +26% | +$5.44M | 0.03% | 229 |
|
|
2020
Q3 | $19.3M | Sell |
125,010
-1,380
| -1% | -$213K | 0.03% | 240 |
|
|
2020
Q2 | $18.7M | Buy |
126,390
+9,795
| +8% | +$1.45M | 0.03% | 227 |
|
|
2020
Q1 | $13.1M | Sell |
116,595
-1,286
| -1% | -$145K | 0.03% | 246 |
|
|
2019
Q4 | $16.4M | Sell |
117,881
-8,986
| -7% | -$1.25M | 0.03% | 256 |
|
|
2019
Q3 | $12.2M | Buy |
126,867
+25,664
| +25% | +$2.47M | 0.02% | 302 |
|
|
2019
Q2 | $11.7M | Sell |
101,203
-6,141
| -6% | -$707K | 0.02% | 314 |
|
|
2019
Q1 | $12.6M | Sell |
107,344
-359
| -0.3% | -$42.3K | 0.02% | 307 |
|
|
2018
Q4 | $6.75M | Buy |
107,703
+19,648
| +22% | +$1.23M | 0.02% | 381 |
|
|
2018
Q3 | $6.24M | Buy |
+88,055
| New | +$6.24M | 0.01% | 451 |
|